Z. Todorovic et al., THE CARDIOVASCULAR EFFECTS OF THE ADMINISTRATION OF L-NAME DURING THEEARLY POSTHEMORRHAGIC PERIOD, General pharmacology, 30(5), 1998, pp. 763-769
1. The effects of the various doses of N-G-nitro-L-arginine methyl est
er (L-NAME, 10 and 30 mg/kg) on some cardiovascular and biochemical pa
rameters during the early posthemorrhagic period were studied in anest
hetized rabbits subjected to hemorrhagic hypovolemia. 2. Hemorrhagic s
hock was produced by intermittent bleeding of 40% of the estimated blo
od volume for 15 min. Blood samples were taken before and after bleedi
ng (0, 15 and 60 min). Simultaneously, the mean arterial pressure (MAP
) and the heart rate (HR) were measured. Hemorrhaged rabbits were trea
ted by L-NAME(10) or t-NAME(30) (10 or 30 mg/kg, IV bolus injection, r
espectively) or the corresponding volumes of saline (0.6 ml, IV bolus)
immediately after the end of bleeding. 3. The observed cardiovascular
parameters (MAP, HR) were significantly reduced after the end of blee
ding in all rabbits. 4. The rise of the MAP was significantly more pro
nounced 30 min after the injection of L-NAME(30) in comparison with th
e corresponding values in the saline (S) group. In contrast, L-NAME(10
) produced only a small, insignificant increase in the MAP in hemorrha
ged rabbits. 5. The L-NAME(30)-induced rise of the MAP was accompanied
by a severe bradycardia, hyperkalemia and an aggravated metabolic aci
dosis, more severe than the corresponding disturbance of the acid-base
status in the S group. The changes in the acid-base parameters were o
bserved both in arterial (pH, excess base) and in venous blood (pH) of
hemorrhaged rabbits. 6. In conclusion, the IV bolus injection of L-NA
ME(30) (immediately after the end of bleeding) produced a significant
increase in the MAP during the first hour after the injury, but the pr
esumable inhibition of the endothelial constitutive nitric oxide synth
ase during the early posthemorrhagic period resulted in severe cardiov
ascular and metabolic disturbances. (C) 1998 Elsevier Science Inc.